The global genitourinary drugs market is expected to grow at a CAGR of around 4% during 2021-2026.
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
The genitourinary system includes kidneys, ureters, bladder, urethra, and genital organs, which play a vital role in reproduction and getting rid of waste products from the body. Its functioning can be hampered on account of congenital abnormalities, iatrogenic injuries, cancer, trauma, infections, hydronephrosis, and inflammation. Due to the rising number of individuals suffering from these diseases, there is a rise in the demand for genitourinary drugs across the globe. Genitourinary drugs help treat the reproductive organs, excretory system, and urinary tract conditions. They are also used in the treatment of bladder spasms and erectile dysfunction and suppressing uterine contractions to prevent preterm labor.
Genitourinary Drugs Market Trends: The increasing risk of genitourinary organ damage represents one of the major factors influencing the growth of the market. Moreover, as genitourinary drugs are effective in treating the pediatric population with chronic kidney failure and urinary tract infections, their sales are increasing around the world. Apart from this, the leading market players are focusing on advancing formulation techniques to introduce drugs that help treat chronic prostate cancer patients who have developed resistance to conventional chemotherapeutic and hormone therapy agents. Furthermore, several multinational companies (MNCs) are collaborating with biopharmaceutical leaders to launch next-generation therapeutics and strengthen their position in the market. This, in confluence with a considerable rise in the number of pipeline drugs in late-stage clinical trials, is contributing to the market growth. Besides this, the increasing funding for research and development (R&D) projects, along with improvements in the healthcare infrastructure sponsored by governing and non-governing agencies of numerous countries, is anticipated to drive the demand for genitourinary drugs in the coming years.
Key Market Segmentation: the analyst provides an analysis of the key trends in each sub-segment of the global genitourinary drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on indication and product.
Breakup by Indication: Prostate Cancer Ovarian Cancer Bladder Cancer Cervical Cancer Renal Cancer Erectile Dysfunction Urinary Tract Infections Urinary Incontinence and Overactive Bladder Sexually Transmitted Diseases Interstitial Cystitis Hematuria Benign Prostatic Hyperplasia
Breakup by Product: Urological Hormonal Therapy Gynecological Anti-infectives Others
Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa
Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report: How has the global genitourinary drugs market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global genitourinary drugs market? What are the key regional markets? What is the breakup of the market based on the indication? What is the breakup of the market based on the product? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global genitourinary drugs market and who are the key players? What is the degree of competition in the industry?
Our reports have been used by over 10K customers, including:
The Global Benign Prostatic Hyperplasia Therapeutics Market size is expected to reach $7.4 billion by 2027, rising at a market growth of 4.6% CAGR during the forecast period. Benign prostatic hyperplasia (BPH) is a benign swelling of the prostate gland that is not malignant. Benign prostatic hypertrophy or benign prostatic blockages...
175 pages •
By The Business Research Company
• Mar 2022
Major players in the corticosteroids therapy market are Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, LEO Pharma, Abbott Laboratories, Bayer and Zizhu Pharma. The global corticosteroids market is expected to grow from $4.85 billion in 2021 to $5.05 billion in 2022 at a compound annual growth...
“Androgen receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Androgen receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type,...
120 pages •
By Infiniti Research Limited
• Mar 2022
Global Bispecific Antibodies for Cancer Market 2022-2026 The analyst has been monitoring the bispecific antibodies for cancer market and it is poised to grow by $ 396.56 mn during 2022-2026, progressing at a CAGR of 9.06% during the forecast period. Our report on the bispecific antibodies for cancer market provides a holistic...
US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights: • US Cancer Antibodies Market Opportunity: > US$ 85 Billion by 2028 • US Cancer Antibodies Market To Witness More Than 200% Absolute Growth • Current & Future market Projections by Drugs & Therapeutic Class •...
Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class (Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, and Others) and Therapy Type (Mono Drug Therapy and Combination Drug Therapy): Global Opportunity Analysis and Industry Forecast, 2021–2030 The global benign prostatic...
175 pages •
By The Business Research Company
• Feb 2022
Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc, New England Biolabs, Promega Corporation, Qiagen, Takara Bio, Merck KGaA, Genscript Biotech Corporation, Life Technologies Corporation, Sigma-Aldrich Corporation, Lucigen Corporation, Synthetic Genomics Inc., Becton,...
“30S Ribosomal Subunit (30S RNA) Inhibitor - Pipeline Insight, 2022” report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 30S Ribosomal Subunit (30S RNA) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action,...
“Dopaminergic Agonist - Pipeline Insight, 2022” report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Dopaminergic Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources...
Therapy
Research And Development
World
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.